Medigene AG Reports 2024 Half-Year Results, Provides Business Update Page 1

• Significant business and scientific progress in the first half of 2024
• Progress on MDG1015 main program with IND application on track for 3Q 2024 and CTA application for 4Q 2024
• New additions to End-to-End Platform technologies and IP portfolio
• Expansion of the partnership with a new research partnership with WuXi Biologics, leveraging Medigene’s best-in-class TCR generation capabilities in August 2024
• Cash flow until July 2025
• Company will host a conference call today, August 14, 2024, at 3:30 PM CEST/9:30 AM EST

Planegg/Martinsried, August 14, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-directed therapies for the treatment of cancer, today reported financial results for the six months ended June 30, 2024 and provided a business update.
The 2024 half-yearly profit report can be found on the website: https://medigene.com/investors-media/reports-presentations/

Select 2024 half-year financial results: